HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B

The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.

By STAT News · May 7, 2026 · via STAT News
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News →

Tags
dealsformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat
DealsFierceBiotech ↗
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s hea…
May 7, 2026
Bayer Buys Perfuse for $2.4B, Targeting Next-Generation Eye Disease Therapy
DealsBriefing
Bayer Buys Perfuse for $2.4B, Targeting Next-Generation Eye Disease Therapy
The $300M upfront deal gives Bayer control of PER-001, a midphase implant for glaucoma and diabetic retinopath…
May 7, 2026
A new company rises from the ashes of Purdue Pharma
DealsPharmaVoice ↗
A new company rises from the ashes of Purdue Pharma
Knoa Pharma will still sell the opioid medications that triggered a national crisis, but with guardrails.…
May 6, 2026